<DOC>
	<DOCNO>NCT03098121</DOCNO>
	<brief_summary>This clinical study evaluate whether grazoprevir elbasvir efficacious , safe , well-tolerated peginterferon alfa plus ribavirin experienced patient inject drug ( PWID ) men sex men ( MSM ) genotype 1 HCV HIV co-infection .</brief_summary>
	<brief_title>Efficacy Tolerability Grazoprevir Elbasvir Peginterferon Alfa Plus Ribavirin Experienced Patients With Chronic Genotype 1 HCV HIV Co-infection : Non-randomised , Open-label Clinical Trial</brief_title>
	<detailed_description>Primary Objective •To ass efficacy grazoprevir 100mg elbasvir 50mg determine proportion sustain virological response 12 week end therapy ( SVR12 ; HCV RNA concentration le 10 IU/ mL follow-up week 12 ) peginterferon alfa plus ribavirin experienced patient genotype 1 HCV HIV co-infection , compare treatment-naïve patient 1 HCV HIV co-infection . Secondary Objective •To ass tolerability grazoprevir 100mg elbasvir 50mg peginterferon alfa plus ribavirin experienced patient measure frequency SAEs AEs lead discontinuation .</detailed_description>
	<mesh_term>Coinfection</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Men nonpregnant woman , least 20 year age chronic genotype 1 HCV HIV coinfection . HCV RNA &gt; 10,000 IU/mL Stable antiretroviral therapy ( ARV ) confirm plasma HIV1 RNA &lt; 200 copies/mL CD4 Tcell count &gt; 100 cells/L peginterferon alfa plus ribavirin failure : null response &lt; 1 log10 IU/mL reduction HCV RNA week 4 ; detectable HCV RNA since week 12 end treatment ; detectable HCV RNA 12 24 week end treatment ; discontinuation peginterferon alfa plus ribavirin due grade 3 grade 4 adverse effect moment . Decompensated liver disease ( presence history ascites , oesophageal gastric variceal bleeding , hepatic encephalopathy , sign advance liver disease ) Liver cirrhosis ChildPugh class B C , ChildTurcottePugh score 6 point albumin 3 g/dL platelet count 75,000/ μL History malignant disease , evidence hepatocellular carcinoma ARV protease inhibitor contain regimen HBsAg HBV core antibody check patient . HBsAg positive patient exclude study . HBV core antibody positive patient closely monitor hepatitis flare HBV reactivation HCV treatment posttreatment followup . Appropriate patient management institute HBV infection clinically indicate .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>